Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist
Obstetrics & Gynecology Science
;
: 69-73, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-34444
ABSTRACT
OBJECTIVE:
The aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM) or gonadotropin-releasing hormone (GnRH) agonist on uterine fibroid shrinkage among Korean women.METHODS:
This retrospective study involved 101 women with symptomatic uterine fibroids who received ulipristal acetate (SPRM, n=51) and leuprolide acetate (GnRH agonist, n=50) for 3 months between November 2013 and February 2015. The fibroid volume was measured both before and after treatment using ultrasonography, computed tomography, and magnetic resonance imaging. The outcomes were compared between the SPRM and GnRH agonist groups.RESULTS:
The median rate of fibroid volume reduction after SPRM treatment was 12.4% (IQR −14.5% to 40.5%) which was significantly lower than the reduction rate observed after GnRH agonist treatment (median 34.9%, IQR 14.7% to 48.6%, P=0.004). 19 of 51 (37.3%) patients with SPRM treatment did not show any response of volume shrinkage, while 7 of 50 (14.0%) women with GnRH agonist showed no response (P=0.007).CONCLUSION:
Short-term SPRM treatment yields lower volume reduction than GnRH agonist treatment in Korean women with symptomatic fibroids. Further large-scale randomized trials are needed to confirm our findings.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Progesterona
/
Imagen por Resonancia Magnética
/
Receptores de Progesterona
/
Estudios Retrospectivos
/
Ultrasonografía
/
Hormona Liberadora de Gonadotropina
/
Leuprolida
/
Leiomioma
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Obstetrics & Gynecology Science
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS